Lallemand Health Solutions is proud to announce an exciting proof-of-concept clinical trial featuring its flagship psychobiotic formula, Cerebiome® at in-cosmetics® global, taking place…
Lallemand Health Solutions invites you to taste its innovative galenic forms at SupplySide West in Las Vegas USA, from October 23-27, 2023.…
Lallemand Health Solutions is strengthening its strategic position in the microbiome field through contract development and manufacturing operations, with the launch of…
Lallemand Health Solutions is very pleased to announce the acquisition of Dietary Pros Inc. from its founder and CEO Dennis Drager. “We…
On Thursday, September 21st, 2023, Lallemand celebrated a significant milestone: 100 years of yeast production in its production plant on rue Préfontaine,…
The Brazilian Health Authorities, ANVISA[1] approved Probiokid® for use in infants and children (from 3-to-36-month-old), reinforcing Lallemand Health Solutions privileged position in…
Lallemand joins the Bureau of the Strategic Orientation Committee of the ‘Grand Défi Ferments du Futur’ and will be represented by four…
As a co-founding partner, Lallemand Health Solutions proudly presents the fourth edition of the Mind, Mood & Microbes International conference on Microbiome-Gut-Brain…
Lallemand Health Solutions will present its probiotic innovations at Vitafoods Europe in Geneva Palexpo, Switzerland, from May 9-11, 2023. Probiotic Breakthrough: Organic…
Apsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome® on the gut…
